CN111632074A - A Chinese and western medicinal composition for treating insomnia and preparation method thereof - Google Patents
A Chinese and western medicinal composition for treating insomnia and preparation method thereof Download PDFInfo
- Publication number
- CN111632074A CN111632074A CN202010730131.0A CN202010730131A CN111632074A CN 111632074 A CN111632074 A CN 111632074A CN 202010730131 A CN202010730131 A CN 202010730131A CN 111632074 A CN111632074 A CN 111632074A
- Authority
- CN
- China
- Prior art keywords
- parts
- maca
- gamma
- aminobutyric acid
- acanthopanax
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 38
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 title claims abstract description 37
- 206010022437 insomnia Diseases 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title description 16
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 106
- 240000000759 Lepidium meyenii Species 0.000 claims abstract description 71
- 235000000421 Lepidium meyenii Nutrition 0.000 claims abstract description 71
- 235000012902 lepidium meyenii Nutrition 0.000 claims abstract description 71
- 239000000843 powder Substances 0.000 claims abstract description 66
- 239000003814 drug Substances 0.000 claims abstract description 55
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 53
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 53
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 44
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 44
- 239000002994 raw material Substances 0.000 claims abstract description 17
- 241000222336 Ganoderma Species 0.000 claims description 9
- 150000001336 alkenes Chemical class 0.000 claims description 8
- 238000000855 fermentation Methods 0.000 claims description 8
- 230000004151 fermentation Effects 0.000 claims description 8
- 238000002137 ultrasound extraction Methods 0.000 claims description 8
- 210000002421 cell wall Anatomy 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 238000012545 processing Methods 0.000 claims description 7
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 229940046011 buccal tablet Drugs 0.000 claims description 2
- 239000006189 buccal tablet Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000011097 chromatography purification Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940126678 chinese medicines Drugs 0.000 claims 1
- 229940126673 western medicines Drugs 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 34
- 230000007958 sleep Effects 0.000 abstract description 25
- 229940079593 drug Drugs 0.000 abstract description 22
- 241001632410 Eleutherococcus senticosus Species 0.000 abstract description 6
- 230000000147 hypnotic effect Effects 0.000 abstract description 6
- 229940125717 barbiturate Drugs 0.000 abstract description 4
- HNYOPLTXPVRDBG-UHFFFAOYSA-N barbituric acid Chemical compound O=C1CC(=O)NC(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-N 0.000 abstract description 4
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 208000019901 Anxiety disease Diseases 0.000 abstract description 3
- 230000036506 anxiety Effects 0.000 abstract description 3
- 230000007774 longterm Effects 0.000 abstract description 3
- 230000003860 sleep quality Effects 0.000 abstract description 3
- 206010062519 Poor quality sleep Diseases 0.000 abstract description 2
- 230000000295 complement effect Effects 0.000 abstract description 2
- 208000033065 inborn errors of immunity Diseases 0.000 abstract description 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 abstract description 2
- 230000001914 calming effect Effects 0.000 abstract 1
- 238000002474 experimental method Methods 0.000 description 22
- 150000001875 compounds Chemical class 0.000 description 19
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 17
- 230000004622 sleep time Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 12
- 229960002275 pentobarbital sodium Drugs 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 210000004369 blood Anatomy 0.000 description 10
- 239000008280 blood Substances 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 101100184147 Caenorhabditis elegans mix-1 gene Proteins 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 230000006872 improvement Effects 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000004587 chromatography analysis Methods 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000005036 nerve Anatomy 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 229910001385 heavy metal Inorganic materials 0.000 description 5
- 229960001412 pentobarbital Drugs 0.000 description 5
- 239000000447 pesticide residue Substances 0.000 description 5
- 210000003169 central nervous system Anatomy 0.000 description 4
- 206010016256 fatigue Diseases 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 239000002858 neurotransmitter agent Substances 0.000 description 4
- 230000028527 righting reflex Effects 0.000 description 4
- 230000004620 sleep latency Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010001497 Agitation Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000033764 rhythmic process Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 230000002936 tranquilizing effect Effects 0.000 description 3
- YVWMHFYOIJMUMN-CYZWUHAYSA-N (6e,8e)-5-oxooctadeca-6,8-dienoic acid Chemical compound CCCCCCCCC\C=C\C=C\C(=O)CCCC(O)=O YVWMHFYOIJMUMN-CYZWUHAYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000001431 Psychomotor Agitation Diseases 0.000 description 2
- 206010038743 Restlessness Diseases 0.000 description 2
- 208000003443 Unconsciousness Diseases 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000006838 adverse reaction Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000003750 conditioning effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000000890 drug combination Substances 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 208000013403 hyperactivity Diseases 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004799 sedative–hypnotic effect Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 208000020685 sleep-wake disease Diseases 0.000 description 2
- 230000036578 sleeping time Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000027109 Headache disease Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 206010043275 Teratogenicity Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 229960000796 barbital sodium Drugs 0.000 description 1
- FTOAOBMCPZCFFF-UHFFFAOYSA-N barbitone sodium Natural products CCC1(CC)C(=O)NC(=O)NC1=O FTOAOBMCPZCFFF-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 208000015606 cardiovascular system disease Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000000517 effect on sleep Effects 0.000 description 1
- 230000001779 embryotoxic effect Effects 0.000 description 1
- 231100000238 embryotoxicity Toxicity 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 229940005583 maca preparation Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 210000001259 mesencephalon Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000013348 organic food Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 210000004560 pineal gland Anatomy 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- RGHFKWPGWBFQLN-UHFFFAOYSA-M sodium;5,5-diethylpyrimidin-3-ide-2,4,6-trione Chemical compound [Na+].CCC1(CC)C([O-])=NC(=O)NC1=O RGHFKWPGWBFQLN-UHFFFAOYSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 210000003523 substantia nigra Anatomy 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000211 teratogenicity Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/254—Acanthopanax or Eleutherococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention discloses a Chinese and western medicine formula for treating insomnia, which comprises the following raw materials in parts by weight: 20-30 parts of sporoderm-broken ganoderma lucidum spore powder, 10-20 parts of Peruvian maca, 5-15 parts of acanthopanax and 8-12 parts of gamma-aminobutyric acid; meanwhile, the invention also provides a preparation method of the Chinese and western medicine for treating insomnia. The Peruvian maca, the wall-broken ganoderma lucidum spore powder and the acanthopanax senticosus are combined and matched according to different dosages, and the effects of calming and hypnosis are enhanced by utilizing the complementary action among the components, the central inhibition effect of barbiturate medicines can be enhanced, the nervous overexcitation can be inhibited, the sleep state can be helped, and the effect of improving the sleep is achieved. Is suitable for people with long-term insomnia, anxiety, poor sleep quality, and hypoimmunity.
Description
Technical Field
The invention relates to the fields of medicines, health-care products and health-care foods, in particular to a Chinese and western medicine formula for treating insomnia and a preparation method thereof.
Background
There is a theory among people: sleep is the best tonic, suggesting the importance of sleep to health.
Insomnia is a subjective experience that the quality or quantity of sleep caused by difficulty in sleeping and/or sleep maintenance of people does not meet normal physiological requirements, and thus the social function in daytime is affected, and is the most common sleep disorder. Today, insomnia is a very common phenomenon with accelerated social rhythm and increased competition. The prevalence rate of insomnia is very high, and the prevalence rate in countries such as Europe and America is about 20-30%, and the prevalence rate in China is about 10-20%.
Insomnia causes fatigue, uneasiness, general malaise, non-semen collection, delayed reaction, headache and attention-deficit disorder, and the greatest influence thereof is mental, and the serious disease causes functional diseases such as schizophrenia, depression, anxiety, vegetative nerve functional disturbance and the like, and various system diseases such as cardiovascular system diseases, digestive system diseases and the like.
The traditional Chinese medicine causes of insomnia are caused by emotional injury, stagnation of liver qi, hyperactivity of heart fire, qi stagnation and blood stasis, internal disturbance of phlegm fire, disharmony of stomach qi, imbalance of qi activity of viscera, failure of yin and yang to follow the channel, failure of yang qi to enter yin, and restlessness of heart, and are mostly the insomnia of excess syndrome. If the heart and spleen are injured due to deficiency of qi and blood, imbalance of yin and yang or excessive thinking, and overstrain, the heart and spleen are nourished, the body is unconscious or blood deficiency is timid, the liver is nourished, the spirit is unconscious or blood deficiency is timid, the liver is nourished or the heart and kidney are not crossed, and the deficient fire is hyperactivity, the insomnia is called deficiency syndrome. In conclusion, dysfunction of zang-fu organs, blockage of pathogenic qi, imbalance of qi, blood, yin and yang, and restlessness of spirit are the basic pathogenesis of insomnia.
Western medicine causes of insomnia are caused by nervous excitation-inhibition imbalance, central inhibitory neurotransmitter deficiency, vegetative nerve dysfunction, biological rhythm disorder and the like.
The existing common non-benzodiazepine medicines for improving sleep disorder improve safety and reduce dependence, but adverse reactions such as daytime sleepiness, dizziness, bitter taste in mouth, nausea, amnesia and the like still occur to a plurality of users. The melatonin products which have the most common sleep improvement effect in the health-care food also have certain side effects and dependence.
Modern people work and live at an accelerated pace, a large number of young and strong people are addicted to computers, the work pressure of white-collar class is high, and the old people suffer from sleep quality reduction, insomnia and the like due to diseases and mental stress. However, most of the sleep-improving drugs have serious adverse reactions and even addiction, and many Chinese herbal medicine preparations have unobvious effects, and particularly, the effective sedative-hypnotic effect is difficult to achieve when the drugs are used alone, so that a large number of insomnia patients are confronted with no proper treatment drugs, and therefore, the drugs for improving sleep more safely and effectively need to be developed.
Disclosure of Invention
The invention aims to overcome the defects that some medicines adopted for improving insomnia have side effects or poor drug effects and patients do not have proper treatment medicines, and provides a Chinese and western medicine formula for treating insomnia and a preparation method thereof.
In order to achieve the purpose, the invention adopts the following technical scheme:
a Chinese and western medicine formula for treating insomnia and a preparation method thereof comprise the following raw materials in parts by weight: 20-30 parts of sporoderm-broken ganoderma lucidum spore powder, 10-20 parts of Peruvian maca, 5-15 parts of acanthopanax and 8-12 parts of gamma-aminobutyric acid.
Preferably, the feed comprises the following raw materials in parts by weight: 22-28 parts of sporoderm-broken ganoderma lucidum spore powder, 12-18 parts of Peruvian maca, 6-14 parts of acanthopanax and 9-11 parts of gamma-aminobutyric acid.
Preferably, the feed comprises the following raw materials in parts by weight: 25 parts of wall-broken ganoderma lucidum spore powder, 15 parts of Peruvian maca, 10 parts of acanthopanax and 10 parts of gamma-aminobutyric acid.
Preferably, the weight ratio of the wall-broken ganoderma lucidum spore powder to the Peruvian maca to the acanthopanax is 20-30:10-20: 5-15.
Preferably, the weight ratio of the sporoderm-broken ganoderma lucidum spore powder to the Peruvian maca to the gamma-aminobutyric acid is 20-30:10-20: 8-12.
The invention also provides a preparation method of the Chinese and western medicine for treating insomnia, which comprises the following steps:
s1: firstly, detecting Peru maca to be used, determining the numerical values of Peru maca alkene and Peru macamide which are special components in Peru maca, and processing the Peru maca meeting the requirements into superfine powder;
s2: breaking cell wall of Ganoderma spore powder by superfine pulverizing;
s3: concentrating and drying the acanthopanax subjected to ultrasonic extraction;
s4: performing chromatographic purification on the gamma-aminobutyric acid produced by fermentation to ensure that the purity of the gamma-aminobutyric acid is over 98 percent;
s5: mixing wall-broken Ganoderma spore powder, Peru Lepidium Meyenii Walp, radix Acanthopanacis Senticosi and gamma-aminobutyric acid, and making into preparations with different shapes.
Preferably, the administration dosage form of the step 5 is tablet, capsule, granule, buccal tablet and beverage preparation.
Preferably, the powder in step 1 and step 2 is larger than 1000 meshes.
Compared with the prior art, the invention has the beneficial effects that:
1. the compound preparation is prepared by adopting the compatibility and combination of natural plants of maca, acanthopanax, ganoderma lucidum spore powder and gamma-aminobutyric acid.
2. The combined compatibility of the western medicine components greatly enhances the effects of sedation and hypnosis, can enhance the central inhibition effect of barbiturate drugs, can inhibit nerve hyperexcitability, helps enter a sleep state, and achieves the effect of improving sleep.
3. The Chinese and western medicine components adopted in the invention can be used as food and medicine dual-purpose resources, and have the advantages of no toxicity, no addiction, no side effect, safety, reliability, other health-care functions of enhancing immunity and the like.
4. The maca and ganoderma lucidum spore powder is wall-broken ultrafine powder, the acanthopanax is an ultrasonic water extract, the purity of gamma-aminobutyric acid is high, the maca and ganoderma lucidum spore powder can be conveniently processed into various required oral preparations, and the absorption and utilization of effective components are increased.
In conclusion, the Peruvian maca, the wall-broken ganoderma lucidum spore powder and the acanthopanax root are combined and distributed, the mutual complementary action among the components is utilized, the tranquilizing and allaying excitement effects are enhanced, the central inhibition effect of barbiturate medicines can be enhanced, the hyperexcitability of nerves can be inhibited, the sleep state can be assisted, and the sleep improvement effect can be achieved. Is suitable for people with long-term insomnia, anxiety, poor sleep quality, and hypoimmunity.
Drawings
FIG. 1 shows the results of experiments on prolonging the sleep time of pentobarbital sodium by using compound MIX-1;
FIG. 2 is the results of the compound preparation MIX-1 in the sub-threshold dose hypnotic experiment of sodium pentobarbital;
FIG. 3 shows the results of experiments on prolonging the sleep time of pentobarbital sodium by using compound MIX-2;
FIG. 4 is the results of the compound preparation MIX-2 in the sub-threshold dose hypnotic experiment of sodium pentobarbital;
FIG. 5 shows the results of experiments on prolonging the sleep time of pentobarbital sodium by using compound MIX;
fig. 6 is the results of compound preparation MIX in the sodium pentobarbital subliminal dose hypnotic experiment.
Detailed Description
The present invention will be further described with reference to the accompanying drawings and examples, which are provided for the purpose of illustration only and are not intended to limit the scope of the invention.
Example 1
A Chinese and western medicine formula for treating insomnia comprises the following raw materials in parts by weight: 20 parts of sporoderm-broken ganoderma lucidum spore powder, 10 parts of Peruvian maca, 5 parts of acanthopanax and 8 parts of gamma-aminobutyric acid.
The invention also provides a preparation method of the Chinese and western medicine for treating insomnia, which comprises the following steps:
s1: firstly, detecting Peru maca to be used, determining the numerical values of Peru maca alkene and Peru macamide which are special components in Peru maca, processing the Peru maca meeting the requirements into superfine powder, and enabling the powder after being crushed to be larger than 1000 meshes;
s2: breaking cell wall of Ganoderma spore powder by superfine pulverizing, wherein the pulverized powder is larger than 1000 mesh;
s3: concentrating and drying the acanthopanax subjected to ultrasonic extraction:
s4: purifying the gamma-aminobutyric acid produced by fermentation by using a chromatographic technique to ensure that the purity of the gamma-aminobutyric acid is more than 98 percent:
s5: uniformly mixing wall-broken ganoderma lucidum spore powder, Peruvian maca, acanthopanax and gamma-aminobutyric acid to prepare preparations with different shapes, and detecting active ingredients, heavy metals and pesticide residues of the raw materials.
Example 2
The invention comprises the following raw materials in parts by weight: 22 parts of sporoderm-broken ganoderma lucidum spore powder, 12 parts of Peruvian maca, 6 parts of acanthopanax and 9 parts of gamma-aminobutyric acid.
The invention also provides a preparation method of the Chinese and western medicine for treating insomnia, which comprises the following steps:
s1: firstly, detecting Peru maca to be used, determining the numerical values of Peru maca alkene and Peru macamide which are special components in Peru maca, processing the Peru maca meeting the requirements into superfine powder, and enabling the powder after being crushed to be larger than 1000 meshes;
s2: breaking cell wall of Ganoderma spore powder by superfine pulverizing, wherein the pulverized powder is larger than 1000 mesh;
s3: concentrating and drying the acanthopanax subjected to ultrasonic extraction:
s4: purifying the gamma-aminobutyric acid produced by fermentation by adopting a chromatographic technique, and ensuring that the purity of the gamma-aminobutyric acid is more than 98 percent:
s5: uniformly mixing wall-broken ganoderma lucidum spore powder, Peruvian maca, acanthopanax and gamma-aminobutyric acid to prepare preparations with different shapes, and detecting active ingredients, heavy metals and pesticide residues of the raw materials.
Example 3
The invention comprises the following raw materials in parts by weight: 25 parts of wall-broken ganoderma lucidum spore powder, 15 parts of Peruvian maca, 10 parts of acanthopanax and 10 parts of gamma-aminobutyric acid.
The invention also provides a preparation method of the Chinese and western medicine for treating insomnia, which comprises the following steps:
s1: firstly, detecting Peru maca to be used, determining the numerical values of Peru maca alkene and Peru macamide which are special components in Peru maca, processing the Peru maca meeting the requirements into superfine powder, and enabling the powder after being crushed to be larger than 1000 meshes;
s2: breaking cell wall of Ganoderma spore powder by superfine pulverizing, wherein the pulverized powder is larger than 1000 mesh;
s3: concentrating and drying the acanthopanax subjected to ultrasonic extraction:
s4: purifying the gamma-aminobutyric acid produced by fermentation by adopting a chromatographic technique, and ensuring that the purity of the gamma-aminobutyric acid is more than 98 percent:
s5: uniformly mixing wall-broken ganoderma lucidum spore powder, Peruvian maca, acanthopanax and gamma-aminobutyric acid to prepare preparations with different shapes, and detecting active ingredients, heavy metals and pesticide residues of the raw materials.
Example 4
The invention comprises the following raw materials in parts by weight: 28 parts of sporoderm-broken ganoderma lucidum spore powder, 18 parts of Peruvian maca, 14 parts of acanthopanax and 11 parts of gamma-aminobutyric acid.
The invention also provides a preparation method of the Chinese and western medicine for treating insomnia, which comprises the following steps:
s1: firstly, detecting Peru maca to be used, determining the numerical values of Peru maca alkene and Peru macamide which are special components in Peru maca, processing the Peru maca meeting the requirements into superfine powder, and enabling the powder after being crushed to be larger than 1000 meshes;
s2: breaking cell wall of Ganoderma spore powder by superfine pulverizing, wherein the pulverized powder is larger than 1000 mesh;
s3: concentrating and drying the acanthopanax subjected to ultrasonic extraction:
s4: purifying the gamma-aminobutyric acid produced by fermentation by adopting a chromatographic technique, and ensuring that the purity of the gamma-aminobutyric acid is more than 98 percent:
s5: uniformly mixing wall-broken ganoderma lucidum spore powder, Peruvian maca, acanthopanax and gamma-aminobutyric acid to prepare preparations with different shapes, and detecting active ingredients, heavy metals and pesticide residues of the raw materials.
Example 5
The invention comprises the following raw materials in parts by weight: 30 parts of sporoderm-broken ganoderma lucidum spore powder, 20 parts of Peruvian maca, 15 parts of acanthopanax and 12 parts of gamma-aminobutyric acid.
The invention also provides a preparation method of the Chinese and western medicine for treating insomnia, which comprises the following steps:
s1: firstly, detecting Peru maca to be used, determining the numerical values of Peru maca alkene and Peru macamide which are special components in Peru maca, processing the Peru maca meeting the requirements into superfine powder, and enabling the powder after being crushed to be larger than 1000 meshes;
s2: breaking cell wall of Ganoderma spore powder by superfine pulverizing, wherein the pulverized powder is larger than 1000 mesh;
s3: concentrating and drying the acanthopanax subjected to ultrasonic extraction:
s4: purifying the gamma-aminobutyric acid produced by fermentation by adopting a chromatographic technique, and ensuring that the purity of the gamma-aminobutyric acid is more than 98 percent:
s5: uniformly mixing wall-broken ganoderma lucidum spore powder, Peruvian maca, acanthopanax and gamma-aminobutyric acid to prepare preparations with different shapes, and detecting active ingredients, heavy metals and pesticide residues of the raw materials.
The function of the wall-broken ganoderma lucidum spore powder is as follows: the ganoderma lucidum can regulate the nervous system through ganoderma lucidum polysaccharide, influence the secretion of the pineal body to melatonin, can regulate biological rhythm, has obvious activity of superoxide dismutase, has the effects of clearing away the first factor, reducing the fatigue of the organism, has obvious tranquilizing effect on the central nervous system by the ganoderma lucidum, and can enhance the central inhibition effect of barbiturate medicaments. The wall-broken ganoderma lucidum spore powder selected by the product is from Kangcheng company of Jinzhai county in Anhui. It has effects in enhancing immune system function, and preventing and treating tumor and cancer; reducing blood pressure and preventing the generation of cardiovascular epidemic diseases; stimulating the secretion of insulin and reducing the blood sugar concentration; accelerating blood microcirculation, improving the oxygen supply capacity of blood, reducing the ineffective oxygen consumption of the organism in a static state, eliminating free radicals in the body, improving the sealing degree of cell membranes of the organism, resisting radiation, improving the capacity of synthesizing DNA, RNA and protein of liver, bone marrow and blood, prolonging the service life and the like;
the Peruvian maca has the following functions: the maca of Peru contains various bioactive substances such as protein, Peru macamide, Peru macaene, various vitamins, trace elements, alpha-linolenic acid and the like, meets various nutritional ingredients required by a human body, and has the effects of resisting fatigue, supplementing physical strength, improving sleep, resisting climacteric, activating fertility, enhancing memory and the like. Peruvian maca contains two special effective components, namely macamide and macaene, has the functions of regulating secretion and balance of hormone and playing a role in chronic conditioning. Maca that this product chose is the direct maca superfine powder of importing from peru to contain higher macamide and maca alkene through detecting.
Acanthopanax root: acanthopanax senticosus is listed as the top grade in Shen nong Ben Cao Jing. The upper product is nontoxic, can lighten the body and prolong the life after being taken for a long time without harm. Acanthopanax senticosus is regarded as a good medicine with the effects of replenishing essence and marrow and resisting aging from old times. Acute toxicity test result of cortex Acanthopanacis indicates that long-term administration of radix Acanthopanacis Senticosi has little toxicity and does not affect sleep and normal sleep. Continuous administration of 6mo of Acanthopanax senticosus extract can prolong the average life without embryotoxicity or teratogenicity. Has effects of invigorating qi, invigorating spleen, invigorating kidney, and tranquilizing mind, and is suitable for treating spleen and kidney yang deficiency, fatigue, asthenia, insomnia, and dreaminess. Is a long-standing nerve-soothing Chinese herbal medicine, and the acanthopanax plays a role in chronic conditioning by tonifying, replenishing essence and nourishing marrow. And has small interference to normal physiological functions. The acanthopanax used by the product is powder which is prepared by adopting water extract obtained by ultrasonic extraction and spray drying.
Gamma-aminobutyric acid: the ganoderma lucidum spore powder directly plays a role in the central nervous system, inhibits the hyperexcitability of nerves, helps to enter a sleep state, can play a better rapid hypnotic role under the assistance of the wall-broken ganoderma lucidum spore powder, is an important inhibitory neurotransmitter of the central nervous system, plays an inhibitory role in the central nervous system, and is gamma-aminobutyric acid (GABA) widely distributed in animals and plants. In animals, GABA is present almost exclusively in nerve tissue, with brain tissue at levels of about 0.1-0.6 mg/g tissue, and immunological studies have shown that the highest concentration is in the mesencephalon substantia nigra. GABA is an important inhibitory neurotransmitter which is deeply researched at present, participates in various metabolic activities, is a naturally-occurring non-protein amino acid, has extremely important physiological functions, can promote brain activation, strengthen brain, improve intelligence, resist epilepsy, promote sleep, beautify and moisten skin, delay brain aging functions, supplement the inhibitory neurotransmitter of a human body, and has good blood pressure lowering efficacy. Promoting kidney function improvement and protection. Inhibiting fatty liver and obesity, and activating liver function. GABA is an ideal ingredient for green food and organic food advocated in the 21 st century, and is also an ideal health food and medicine for preventing and treating senile diseases. The gamma-aminobutyric acid used in the product is a product purified by bacillus subtilis fermentation and chromatographic techniques, and the effect of the gamma-aminobutyric acid has a direct relation with the product purification. The purity of the gamma-aminobutyric acid used in the product is more than 98%.
Experimental example 1
1. Purpose of the experiment: the effect of four different individual drugs and different drug combinations on prolonging the sleep time of pentobarbital sodium was investigated.
2. The experimental method comprises the following steps: 60 ICR mice (18-22 g) are prepared, divided into 6 groups, 10 mice are prepared in each group, then wall-broken ganoderma lucidum spore powder, Peru maca, acanthopanax and gamma-aminobutyric acid are prepared, and then according to the amount in example 3, Peru maca, acanthopanax and ganoderma lucidum are uniformly mixed, wherein the mixture is MIX-1, the acanthopanax, ganoderma lucidum and gamma-aminobutyric acid, the mixture is MIX-2, the Peru maca, the acanthopanax, gamma-aminobutyric acid and the ganoderma lucidum are MIX, and the mixture is MIX.
3. The experimental scheme is as follows: the 6 groups of ICR mice are subjected to intragastric administration twice a day as shown by the abscissa of the graph according to the group and the administration dose, the experiment is carried out after 7 days of continuous administration, a preliminary experiment is carried out before a formal experiment, the dose (30-60mg/kg) of pentobarbital sodium for enabling the animals to fall asleep at 100% without causing the animals to sleep too long is determined, and the formal experiment is carried out by using the dose. The dose of sodium pentobarbital used was determined in preliminary experiments to be 45 mg/kg. 1h after the animals are dosed for the last time, pentobarbital sodium is injected into the abdominal cavity of each group of animals, the injection amount is 0.2ml/20g, and the time from disappearance of righting reflex to restoration of righting reflex is recorded as the sleeping time of the animals.
4. Data statistics and analysis: the sleep time is measured data, variance analysis is adopted, however, the homogeneity test of the variance is firstly carried out according to the variance analysis program, the F value is calculated, the F value is less than F0.05, and the conclusion is that: the difference between the average numbers of all groups is not significant; f value is more than or equal to F0.05, P is less than or equal to 0.05, and statistics is carried out by a pairwise comparison method of mean values between a plurality of experimental groups and a control group; carrying out appropriate variable conversion on the data with non-normal or uneven variance, and counting by using the converted data after meeting the homogeneity requirement of the normal or uneven variance; if the variable still does not reach the goal of being normal or uniform in variance after conversion, statistics is carried out by adopting a rank sum test. The sleep time data of six groups of mice experiments were compared and the results are shown in figures 1, 3 and 5.
5. The experimental results are as follows:
from figure 1, it can be seen that the sleep time of the maca + acanthopanax group and the MIX-1 group of the compound preparation is increased compared with that of the control group, and the statistical significance requirement (p <0.01) is met, which indicates that the MIX-1 of the compound preparation has a certain improvement effect on the sleep time length. As can be seen from FIG. 3, the sleep time of the Ganoderma lucidum spore powder group + Acanthopanax senticosus group and the MIX-2 group, which are compound preparations, is increased compared with the control group, and respectively reaches the statistical significance requirements (p <0.01) and (p <0.001), which indicates that the MIX-2 group, which is a compound preparation, has a certain improvement effect on the sleep time length. From fig. 5, it can be seen that the sleep time of the compound preparation MIX group is increased compared with the control group, and the statistical significance requirement (p <0.05) is achieved, which indicates that the compound preparation MIX has a certain improvement effect on the sleep time length. In combination, the effect of the two medicines is better than that of the single medicine, and the effect of the three medicines is better than that of the two medicines.
Experimental example 2
1. Purpose of the experiment: study of the Effect of four different Individual drugs and different drug combinations on the sleep latency experiments of sodium pentobarbital
2. The experimental method comprises the following steps: 60 ICR mice (18-22 g) are prepared, divided into 6 groups, 10 mice are prepared in each group, then wall-broken ganoderma lucidum spore powder, Peru maca, acanthopanax and gamma-aminobutyric acid are prepared, and then according to the amount in example 3, Peru maca, acanthopanax and ganoderma lucidum are uniformly mixed, wherein the mixture is MIX-1, the acanthopanax, ganoderma lucidum and gamma-aminobutyric acid, the mixture is MIX-2, the Peru maca, the acanthopanax, gamma-aminobutyric acid and the ganoderma lucidum are MIX, and the mixture is MIX.
3. The experimental scheme is as follows: groups of 6 ICR mice were plotted on the abscissa according to group and dose. The administration was performed twice daily by gavage for 7 days. 1h after the animals are subjected to the last administration, 45mg/kg of pentobarbital sodium is injected into the abdominal cavity of each group of animals, the injection amount is 0.2ml/20g, the disappearance of righting reflex after the injection of the pentobarbital sodium is taken as an index, and the time from the end of the injection of the pentobarbital sodium to the disappearance of the righting reflex is recorded as a sleep latency period.
4. Data statistics and analysis: the same as in experimental example 1. The results of the experimental sleep latency time differences of six groups of mice are shown in fig. 2, 4 and 6.
5. The experimental results are as follows:
from fig. 2, it can be found that the administration of maca + acanthopanax plus group and MIX-1 group both significantly shortens the sleeping latency time of experimental animals, and the statistical significance (p <0.01) and (p <0.001) are respectively provided compared with the control group, which indicates that the compound preparation MIX-1 can accelerate the sleeping time and improve the sleep. From fig. 4, it can be found that the administration of the ganoderma lucidum spore powder group, the acanthopanax senticosus group and the MIX-2 group both significantly shortens the sleep-onset latency time of experimental animals, and has statistical significance (p <0.01) and (p <0.001) compared with a control group, respectively, which indicates that the compound preparation MIX-2 can accelerate the sleep-onset time and improve the sleep. From fig. 6, it can be seen that the administration of MIX group significantly shortens the sleeping latency time of experimental animals, and has statistical significance (p <0.001) compared with the control group, which indicates that the compound preparation MIX can accelerate the sleeping latency time and improve sleep. In combination, the effect of the two medicines is better than that of the single medicine, and the effect of the three medicines is better than that of the two medicines.
And (4) experimental conclusion: according to the method for testing the sleep improvement function of the health care product, two of an experiment for prolonging the sleep time of the pentobarbital sodium, an experiment for hypnotizing the pentobarbital sodium (or the barbital sodium) at subthreshold dose and an experiment for sleep latency of the pentobarbital sodium are positive, no obvious direct sleep effect exists, and the positive result of the experiment of the animal with the sleep improvement function of the test sample can be judged. The experimental results show that the compound maca preparation has the function of improving sleep.
In conclusion, through comparison of an MIX-1 group, an MIX-2 group and an MIX group in two experiments, after four medicines are uniformly mixed according to different components and are fed to animals, the animals quickly fall asleep, the sleeping effect is faster, the purposes of medical and health combination are achieved due to the fact that the components comprise Peruvian maca, wall-broken ganoderma lucidum spore powder, acanthopanax and gamma-aminobutyric acid, the qi and blood and yin and yang in human bodies are adjusted after long-time use, the health and the immunity of the human bodies are improved, the patients can quickly fall asleep when the medicines are reduced in taking, side effects are avoided, the patients cannot depend on the medicines for a long time, the selection of the components of the compound preparation is based on the fact that the compound preparation has sufficient research data, has the adjusting effect on nerves and endocrine, the sleep can be improved, and the proper compatible dosage is further discovered through combination under the condition of different dosages, the sedative-hypnotic effect is enhanced through pharmacological research, and the recommended dose for human is about 2-10 g/person.day (60 kg.BW).
The above description is only for the preferred embodiment of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art should be considered to be within the technical scope of the present invention, and the technical solutions and the inventive concepts thereof according to the present invention should be equivalent or changed within the scope of the present invention.
Claims (8)
1. A Chinese and western medicine formula for treating insomnia is characterized by comprising the following raw materials in parts by weight: 20-30 parts of sporoderm-broken ganoderma lucidum spore powder, 10-20 parts of Peruvian maca, 5-15 parts of acanthopanax and 8-12 parts of gamma-aminobutyric acid.
2. The traditional Chinese medicine and western medicine formula for treating insomnia according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 22-28 parts of sporoderm-broken ganoderma lucidum spore powder, 12-18 parts of Peruvian maca, 6-14 parts of acanthopanax and 9-11 parts of gamma-aminobutyric acid.
3. The traditional Chinese medicine and western medicine formula for treating insomnia according to claim 1, which is characterized by comprising the following raw materials in parts by weight: 25 parts of wall-broken ganoderma lucidum spore powder, 15 parts of Peruvian maca, 10 parts of acanthopanax and 10 parts of gamma-aminobutyric acid.
4. The traditional Chinese medicine and western medicine formula for treating insomnia according to claim 1, wherein the weight ratio of the wall-broken ganoderma lucidum spore powder, the Peruvian maca and the acanthopanax is 20-30:10-20: 5-15.
5. The traditional Chinese medicine and western medicine formula for treating insomnia according to claim 1, wherein the weight ratio of the sporoderm-broken ganoderma lucidum spore powder, the Peruvian maca and the gamma-aminobutyric acid is 20-30:10-20: 8-12.
6. A preparation method of Chinese and western medicines for treating insomnia is characterized by comprising the following steps:
s1: firstly, detecting Peru maca to be used, determining the numerical values of Peru maca alkene and Peru macamide which are special components in Peru maca, and processing the Peru maca meeting the requirements into superfine powder;
s2: breaking cell wall of Ganoderma spore powder by superfine pulverizing;
s3: concentrating and drying the acanthopanax subjected to ultrasonic extraction:
s4: performing chromatographic purification on the gamma-aminobutyric acid produced by fermentation to ensure that the purity of the gamma-aminobutyric acid reaches 98%:
s5: mixing wall-broken Ganoderma spore powder, Peru Lepidium Meyenii Walp, radix Acanthopanacis Senticosi and gamma-aminobutyric acid, and making into dosage form.
7. The method for preparing a Chinese and western medicine for treating insomnia according to claim 6, wherein the dosage form of the administration in step (5) is tablet, capsule, granule, buccal tablet and beverage preparation.
8. The method for preparing a Chinese and western medicine for treating insomnia according to claim 6, wherein the powder in step (1) and step (2) are both larger than 1000 mesh.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010730131.0A CN111632074A (en) | 2020-07-27 | 2020-07-27 | A Chinese and western medicinal composition for treating insomnia and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010730131.0A CN111632074A (en) | 2020-07-27 | 2020-07-27 | A Chinese and western medicinal composition for treating insomnia and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111632074A true CN111632074A (en) | 2020-09-08 |
Family
ID=72324123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010730131.0A Pending CN111632074A (en) | 2020-07-27 | 2020-07-27 | A Chinese and western medicinal composition for treating insomnia and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111632074A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112568429A (en) * | 2020-12-18 | 2021-03-30 | 广州白云山汉方现代药业有限公司 | Gamma-aminobutyric acid ganoderma lucidum polysaccharide health food composition and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006728A (en) * | 2012-12-11 | 2013-04-03 | 四川科伦药物研究有限公司 | Pharmaceutical composition for enhancing immunity as well as preparation method and application thereof |
| CN105213455A (en) * | 2015-11-10 | 2016-01-06 | 南京路诗玛生物科技有限公司 | Medicine of a kind of improving water flood and uses thereof |
| CN105725211A (en) * | 2016-03-04 | 2016-07-06 | 广州万康保健品有限公司 | Food health product for improving sleep and preparation method thereof |
-
2020
- 2020-07-27 CN CN202010730131.0A patent/CN111632074A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006728A (en) * | 2012-12-11 | 2013-04-03 | 四川科伦药物研究有限公司 | Pharmaceutical composition for enhancing immunity as well as preparation method and application thereof |
| CN105213455A (en) * | 2015-11-10 | 2016-01-06 | 南京路诗玛生物科技有限公司 | Medicine of a kind of improving water flood and uses thereof |
| CN105725211A (en) * | 2016-03-04 | 2016-07-06 | 广州万康保健品有限公司 | Food health product for improving sleep and preparation method thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112568429A (en) * | 2020-12-18 | 2021-03-30 | 广州白云山汉方现代药业有限公司 | Gamma-aminobutyric acid ganoderma lucidum polysaccharide health food composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103784611B (en) | It is a kind of that there is improvement sleep to help to alleviate composition and its application of pressure | |
| CN104173493A (en) | Pharmaceutical composition with effect of improving sleep as well as preparation method and application of pharmaceutical composition | |
| CN103461631A (en) | Tea sugar food and making method thereof | |
| CN111248370A (en) | Liquid beverage with function of conditioning sleep disorder | |
| CN112294924A (en) | Heart-nourishing and nerve-soothing pharmaceutical composition and preparation method and application thereof | |
| US9707262B2 (en) | Composition with anoxia-tolerant and anti-fatigue effects and use thereof | |
| CN113115940A (en) | Heart calming and sleep aiding composition as well as preparation method and application thereof | |
| CN105708970B (en) | A kind of health food with function of blood sugar reduction | |
| CN111840394B (en) | Pharmaceutical composition for insomnia and preparation method thereof | |
| CN105851185A (en) | Biscuit having anti-fatigue efficacy and preparation method thereof | |
| CN111632074A (en) | A Chinese and western medicinal composition for treating insomnia and preparation method thereof | |
| CN112843174A (en) | Traditional Chinese medicine composition with functions of tonifying spleen, nourishing heart and soothing nerves, preparation method and application | |
| CN102885346A (en) | Wheat, jujube and rose beverage for nourishing heart and soothing nerves and preparation method thereof | |
| CN105920198B (en) | Cell wall-broken micropowder with blood replenishing effect and preparation method thereof | |
| US20230125425A1 (en) | Traditional chinese medicine extract composition with function of regulating depressive emotion and preparation method and traditional chinese medicine preparation thereof | |
| CN115886252A (en) | Food composition for promoting sleep and regulating depression mood and preparation method thereof | |
| CN104957561A (en) | Sleep improving and pressure relieving composition and preparation thereof | |
| CN111298020B (en) | Traditional Chinese medicine composition with anti-fatigue effect and preparation method and application thereof | |
| CN114377109A (en) | Nerve-soothing and sleep-aiding composition and preparation method and application thereof | |
| CN115089661A (en) | Application of ginseng composition for assisting in regulating endocrine metabolism and resisting and preventing cancer | |
| CN100364450C (en) | Alcohol-dissolving liver-protecting healthy food | |
| CN112220772A (en) | Sleep-aiding and sleep-helping effervescent tablet and preparation method thereof | |
| CN113101344B (en) | Traditional Chinese medicine enzyme and preparation method thereof | |
| CN110368456A (en) | A kind of bamboo-leaves flavones composition for helping to improve sleep | |
| CN103599221B (en) | Electuary containing Radix Ginseng powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200908 |
|
| RJ01 | Rejection of invention patent application after publication |